Glucagon-like Peptide-1 Receptor Agonists: New Evidence of Kidney and Cardiovascular Protection From the FLOW and SELECT Trials
Authors:
- 26 September 2024
- journal article
- editorial
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 85 (1) , 115-118
Abstract
No abstract availableFunding Information
- Bayer
- Boehringer Ingelheim
This publication has 14 references indexed in Scilit:
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 DiabetesNew England Journal of Medicine, 2024
- Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trialNature Medicine, 2024
- Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trialNature Medicine, 2024
- Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesNew England Journal of Medicine, 2023
- Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products–induced inflammationKidney International, 2023
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trialsThe Lancet Diabetes & Endocrinology, 2021
- Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor AgonistsAdvances in Chronic Kidney Disease, 2021
- Remission and progression of pre-existing micro- and macroalbuminuria over 15 years after bariatric surgery in Swedish Obese Subjects studyInternational Journal of Obesity, 2020
- Incidence of end-stage renal disease following bariatric surgery in the Swedish Obese Subjects StudyInternational Journal of Obesity, 2018
- Effects of Bariatric Surgery on Mortality in Swedish Obese SubjectsNew England Journal of Medicine, 2007